Zhu Licheng, Lei Yu, Huang Jia, An Yahang, Ren Yanqiao, Chen Lei, Zhao Huangxuan, Zheng Chuansheng
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2023 Apr 26;13:1172292. doi: 10.3389/fonc.2023.1172292. eCollection 2023.
Hepatocellular carcinoma (HCC) is a highly refractory cancer and the fourth leading cause of cancer-related mortality worldwide. Despite the development of a detailed treatment strategy for HCC, the survival rate remains unsatisfactory. Oncolytic virus has been extensively researched as a new cancer therapeutic agent in the treatment of HCC. Researchers have designed a variety of recombinant viruses based on natural oncolytic diseases, which can increase the targeting of oncolytic viruses to HCC and their survival in tumors, as well as kill tumor cells and inhibit the growth of HCC through a variety of mechanisms. The overall efficacy of oncolytic virus therapy is known to be influenced by anti-tumor immunity, toxic killing effect and inhibition of tumor angiogenesis, etc. Therefore, a comprehensive review of the multiple oncolytic mechanisms of oncolytic viruses in HCC has been conducted. So far, a large number of relevant clinical trials are under way or have been completed, and some encouraging results have been obtained. Studies have shown that oncolytic virus combined with other HCC therapies may be a feasible method, including local therapy, chemotherapy, molecular targeted therapy and immunotherapy. In addition, different delivery routes for oncolytic viruses have been studied so far. These studies make oncolytic virus a new and attractive drug for the treatment of HCC.
肝细胞癌（HCC）是一种高度难治性癌症，也是全球癌症相关死亡的第四大主要原因。尽管针对HCC已制定了详细的治疗策略，但其生存率仍不尽人意。溶瘤病毒作为一种新型癌症治疗药物，在HCC治疗中已得到广泛研究。研究人员基于天然溶瘤病毒设计了多种重组病毒，这些重组病毒能够增强溶瘤病毒对HCC的靶向性及其在肿瘤中的存活能力，还能通过多种机制杀死肿瘤细胞并抑制HCC的生长。已知溶瘤病毒疗法的总体疗效受抗肿瘤免疫、毒性杀伤作用和抑制肿瘤血管生成等因素影响。因此，本文对溶瘤病毒在HCC中的多种溶瘤机制进行了全面综述。到目前为止，大量相关临床试验正在进行或已经完成，并取得了一些令人鼓舞的结果。研究表明，溶瘤病毒联合其他HCC治疗方法可能是一种可行的方法，包括局部治疗、化疗、分子靶向治疗和免疫治疗。此外，迄今为止，人们还研究了溶瘤病毒的不同给药途径。这些研究使溶瘤病毒成为一种治疗HCC的新型且有吸引力的药物。
